"Petition unveils unnerving reports on potential carcinogenicity of GLP-1 mimics."

"Butler says it is no wonder that Novo Nordisk bristles in response to his publications. “The global market for type 2 diabetes drugs is worth US$20 billion,” he says. “These drugs are the only ones that manufacturers have that are not off-patent, so if they disappear, they’d have nothing.” Global sales of Victoza reached $310 million last year."

http://www.nature.com/news/debate-on-diabetes-drugs-gathers-pace-1.10548